A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1
This research is investigating a new medication, ALE1, for adults with a rare genetic bone condition called Hypophosphatasia (HPP). HPP affects how strong bones are. The study has two main parts. First, it will check if ALE1 is safe and how the body handles it in healthy adult volunteers. Then, it will look at how ALE1 works in adults who have HPP. Researchers want to understand how much of the medicine to give and how well it helps. Some people in the study will receive ALE1, while others will receive a dummy medicine called a placebo. This helps scientists compare the effects of the real medicine accurately. It's a key step in developing new treatments for HPP.
En un coup d'œil
De quoi parle cette étude ?
This study is exploring a new potential medicine, called ALE1, for a rare inherited condition called Hypophosphatasia (HPP). If you have HPP, your body struggles to make enough of an important chemical called alkaline phosphatase, which is vital for building strong bones and teeth. This can lead to bones that are softer and more easily broken.
The main goal of this study is to find out if ALE1 is safe for people, how much of it the body uses, and what effects it has. The research is being done in two main steps. First, it will involve healthy adult volunteers to check for safety and how the body handles the medicine. This is a very important first step for any new medicine. Once a good safety profile is established, the study will then look at adults who have been diagnosed with HPP.
In both parts of the study, some participants will receive the new medicine ALE1, and others will receive a 'placebo', which looks like the medicine but doesn't contain any active ingredients. This is a standard way to get accurate results and see if the new medicine really makes a difference compared to no treatment. This type of research, known as a Phase 1/2a study, is crucial for understanding new treatments and eventually making them available to people who need them.
Points clés
- This study is testing a new medicine (ALE1) for Hypophosphatasia (HPP).
- It will first check safety in healthy adults, then how it works in adults with HPP.
- Some participants will receive ALE1, others a dummy medicine (placebo).
- La participation implique des visites régulières à la clinique pour des contrôles et des tests.
- You can choose to leave the study at any time.
- Ages 18-50, both sexes, with or without HPP (depending on study part).
Qui peut être éligible ?
To join the first part of this study, you need to be a generally healthy adult. This means you don't have any major ongoing health problems or a significant medical history that would concern the study doctors. Essentially, the doctors will check to make sure you're in good overall health.
For the second part of the study, you must be an adult who has been diagnosed with Hypophosphatasia (HPP). This diagnosis needs to be confirmed by a genetic test showing a fault in the ALPL gene, which is known to cause HPP.
There are also some reasons why you might not be able to join. For instance, if you have had other conditions that affect your bones or how your body handles minerals. Also, if you've recently had a bone fracture (within the last 12 weeks), or if you've previously been treated for HPP or other bone-weakening conditions with certain types of advanced medicines, you might not be suitable.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous entre 18 et 50 ans ?
- If you have HPP, has it been confirmed by a genetic test?
- Do you have any other significant ongoing health problems?
- Have you had a bone fracture in the last 3 months (12 weeks)?
- Have you been treated for HPP before with enzyme replacement therapy or similar advanced medicines?
- Do you have conditions like hyperparathyroidism or hypoparathyroidism (unless it's due to your HPP)?
En quoi consiste la participation ?
If you decide to take part in this study, you will be assigned to either receive the new medicine, ALE1, or a 'dummy' medicine called a placebo. You won't know which one you are getting, and neither will your study doctor, which helps to keep the results fair and unbiased. The study will involve a number of visits to the clinic, where you'll have medical checks, blood tests, and other assessments to monitor your health and see how the medicine is working. You'll be given instructions on how to take the study medicine. The total length of your participation in the study and the total number of visits will be explained in detail by the study team, and you will have regular follow-up appointments. You can withdraw from the study at any time.
Risques et avantages potentiels
Emplacements (3)
- Universitätsklinikum WürzburgCode postal vérifiéWürzburg, Germany· Recrutement
- New Zealand Clinical ResearchCode postal vérifiéGrafton, New Zealand· Recrutement
- Fortrea Clinical Research UnitCode postal vérifiéLeeds, United Kingdom· Recrutement
Questions fréquentes
Qu'est-ce que l'hypophosphatasie (HPP) ?
HPP is a rare genetic condition that affects how your bones and teeth develop, often making them softer and weaker than they should be.
What is ALE1?
ALE1 is a new medicine that researchers are studying to see if it can help people with Hypophosphatasia.
Que signifie 'contrôlé par placebo' ?
It means some people get the new medicine, and others get a 'dummy' medicine (placebo) that looks the same but has no active ingredients. This helps researchers compare the real effects.
Why can't I join if I've had certain other bone treatments?
The researchers want to clearly understand the effects of ALE1 on its own, so previous treatments for HPP or bone conditions could make it harder to see the true results.
Combien de temps durera l'étude ?
The exact total duration of your participation, including visits and follow-ups, will be fully explained by the study team if you are eligible and interested.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.